Bank of New York Mellon Corp Sells 2,505 Shares of iShares Nasdaq Biotechnology ETF (IBB)

Share on StockTwits

Bank of New York Mellon Corp cut its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 5.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,419 shares of the financial services provider’s stock after selling 2,505 shares during the quarter. Bank of New York Mellon Corp owned about 0.06% of iShares Nasdaq Biotechnology ETF worth $4,380,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of IBB. Lockheed Martin Investment Management Co. increased its position in shares of iShares Nasdaq Biotechnology ETF by 173.9% during the 4th quarter. Lockheed Martin Investment Management Co. now owns 417,400 shares of the financial services provider’s stock worth $40,250,000 after purchasing an additional 265,000 shares during the last quarter. Morgan Stanley grew its position in iShares Nasdaq Biotechnology ETF by 3.7% in the 3rd quarter. Morgan Stanley now owns 4,026,110 shares of the financial services provider’s stock valued at $490,944,000 after acquiring an additional 143,209 shares in the last quarter. Ferguson Wellman Capital Management Inc. grew its position in iShares Nasdaq Biotechnology ETF by 546.5% in the 4th quarter. Ferguson Wellman Capital Management Inc. now owns 83,921 shares of the financial services provider’s stock valued at $8,092,000 after acquiring an additional 70,941 shares in the last quarter. Bank of Montreal Can grew its position in iShares Nasdaq Biotechnology ETF by 21.2% in the 4th quarter. Bank of Montreal Can now owns 356,482 shares of the financial services provider’s stock valued at $34,376,000 after acquiring an additional 62,272 shares in the last quarter. Finally, Private Advisor Group LLC grew its position in iShares Nasdaq Biotechnology ETF by 129.4% in the 4th quarter. Private Advisor Group LLC now owns 90,418 shares of the financial services provider’s stock valued at $8,719,000 after acquiring an additional 51,001 shares in the last quarter. 65.59% of the stock is owned by institutional investors and hedge funds.

NASDAQ IBB opened at $109.39 on Wednesday. iShares Nasdaq Biotechnology ETF has a 1-year low of $89.01 and a 1-year high of $122.97.

COPYRIGHT VIOLATION NOTICE: “Bank of New York Mellon Corp Sells 2,505 Shares of iShares Nasdaq Biotechnology ETF (IBB)” was posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://macondaily.com/2019/04/17/bank-of-new-york-mellon-corp-sells-2505-shares-of-ishares-nasdaq-biotechnology-etf-ibb.html.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Recommended Story: What are defining characteristics of a correction?

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.